Antifibrinolytic agents in off-pump cardiac surgery: analysis of blood loss, safety and cost-effectiveness
Authors:
T. Vaněk 1; M. Jareš 1; R. Fajt 1; Z. Straka 1; M. Malý 2
Authors‘ workplace:
Kardiochirurgická klinika, Univerzita Karlova, 3. LF a FNKV, Praha
1; Oddělení biostatistiky a informatiky, SZÚ, Praha
2
Published in:
Anest. intenziv. Med., 17, 2006, č. 1, s. 6-13
Category:
Anaesthesiology - Original Paper
Overview
Objective:
To compare the haemostatic effects of fibrinolytic inhibitors (tranexamic acid, aprotinin) vs. placebo in off-pump coronary artery bypass surgery and to evaluate the impact of this therapy on cost-effectiveness.
Design:
Prospective, randomized, double-blind study.
Setting:
University Teaching Hospital, Prague, Czech Republic.
Material and Method:
100 patients were enrolled in the study and 91 of them were assessed (group A, n = 32, tranexamic acid 1 g before skin incision followed by continuous infusion at 200 mg/h; group B, n = 29, aprotinin 1,000,000 IU before skin incision and 250,000 IU/h afterwards; group C, n = 30, placebo).
Results:
Highly significant inter-group differences were found in the cumulative blood loss within 4 h (geometric means [95% confidence intervals] – group A: 89.3 [72.7, 109.8] mL, group B: 72.3 [49.2, 106.3] mL and group C: 192.3 [151.8, 243.5] mL) (P < 0.001), within 8 h (group A: 152.1 [120.7, 191.6] mL, group B: 130.3 [88.1, 192.8] mL and group C: 283.8 [226.0, 356.3] mL) (P = 0.001), and within 24 h postoperatively (group A: 410.3 [337.6, 498.6] mL, group B: 345.8 [256.0, 398.2] mL and group C: 619.8 [524.3, 732.8] mL) (P < 0.001). At all time points, group C (placebo) was significantly distinct from the groups treated with fibrinolytic inhibitors (groups A, B). However, no essential differences between groups A and B were found. Treated groups did not demonstrate postoperative increase in mean levels of myocardial enzymes compared with group C. No statistically significant inter-group difference was found in the number of re-transfused patients (either packed red blood cells, P = 0.119, or fresh-frozen plasma, P = 0.118) during the first 24 h postoperatively, but the number of re-transfused patients during the hospital stay was statistically significantly higher in group C compared with group B (P = 0.002). Cost effectiveness of the antifibrinolytic agent and blood product treatment seems to be on average the most favourable in the tranexamic acid group.
Conclusion:
Both tranexamic acid and aprotinin seem to be similarly effective in the reduction of postoperative blood loss in off-pump cardiac surgery. Tranexamic acid appears to be a cost-effective and safe alternative to aprotinin.
Key words:
tranexamic acid – aprotinin – cardiac surgical procedures – off-pump coronary artery bypass
Labels
Anaesthesiology, Resuscitation and Inten Intensive Care MedicineArticle was published in
Anaesthesiology and Intensive Care Medicine
![Issue 1](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/9ace9fb09359af9079732221b8376fc9.jpeg)
2006 Issue 1
Most read in this issue
- Vascular anaesthesia at the beginning of the third millenium
- The cardiovascular system in the elderly and perioperative risk
- Antifibrinolytic agents in off-pump cardiac surgery: analysis of blood loss, safety and cost-effectiveness
- The prospective study on the effect of a preemptive long-term postoperative administration of a low-dose ketamine on the incidence of chronic post-mastectomy pain